PeriGen Appoints CEO

PeriGen, a provider of perinatal-specific clinical decision support for hospitals, has appointed Matthew Sappern as chief executive officer. Sappern joins PeriGen from his position as senior vice president, client sales at Allscripts, a $1.3 billion electronic medical records provider. PeriGen’s investors include Trident Capital, Galen Partners and Salmon River Capital.


PeriGen, Inc., the leader in perinatal-specific clinical decision support for hospitals, announced today that it has appointed Matthew Sappern as Chief Executive Officer, effective immediately.

Sappern, 45, joins PeriGen from his position as Senior Vice President, Client Sales at Allscripts, a $1.3 billion global leader in the electronic medical records industry. At Allscripts, Sappern’s Client Sales team achieved record bookings in 2011. Sappern joined Allscripts in 2010 following its merger with Eclipsys, where he served as a corporate officer and Senior Vice President of Professional Services responsible for directing the Services division, encompassing the company’s consulting, implementation, and education and training services. Before that, he served as Senior Vice President of Technology Solution Services at Eclipsys, which he joined in 2003, after serving in leadership roles at WebMD, Time Warner, Primedia and Young & Rubicam.

John Reardon, member of PeriGen’s Board of Directors, and Managing Director of Trident Capital, said, “We are delighted that Matt Sappern is coming on board to lead PeriGen. Matt’s proven expertise in driving the growth of sophisticated, groundbreaking healthcare IT products is a great fit for PeriGen.”

David Jahns, member of PeriGen’s Board of Directors, and Managing Director of Galen Partners, said, “We are confident that as chief executive officer Matt Sappern will significantly expand PeriGen’s market footprint so that the breadth and depth of its innovative, clinical decision support technologies can touch more patients and improve the bottom line at more healthcare systems in North America and around the world.”

Sappern said, “Hospital leaders are increasingly demanding tangible returns in shorter cycles on IT investment. As this pressure mounts, the spotlight will swing quickly from broad enterprise systems with generic feature sets to departmental systems that leverage deep expertise to generate more focused, and immediate clinical and financial benefits. The future of healthcare IT lies in deep and specific clinical decision support delivered through departmental rather than enterprise solutions. I’m thrilled to be with PeriGen because I know its unique application of expert systems and clinical decision support is already addressing an acute need in the obstetrics space in a way that generates immediate, tangible returns — clinically and financially — for our hospital customers.”

Executives from MedStar Health, a 9-hospital system in the metro Washington, D.C. area, made a presentation at the American Society for Healthcare Risk Management Annual Conference and Exhibition in October 2011 demonstrating how a PeriGen solution drove a 50% drop in both the frequency and severity of obstetrics and labor and delivery claims. Similarly, executives from Banner Health, a 25-hospital system headquartered in Phoenix, Arizona, outlined how they achieved a reduction in Banner’s self-insured reserves by $5.6 million per year after installing a PeriGen solution. PeriGen also partners with global insurers and brokers such as Beazley PLC and Willis Group Holdings who recognize the impact of PeriGen’s solutions in reducing risk and improving the quality of care delivered by offering premium reductions to insured hospitals that use certain PeriGen products.

Representing the next generation of clinical decision support tools and encompassing more than 6,000 protocols, best practices, and guidelines for obstetrics, PeriGen’s solutions provide real-time, interactive guidance at the patient’s bedside to facilitate the delivery of consistent, repeatable high-quality care for mothers and babies.

PeriGen’s perinatal suite includes the PeriBirth(R) clinical decision support system for obstetrics and the PeriCALM(R) fetal monitoring solution. Embedded with artificial intelligence, all of PeriGen’s solutions promote the highest standard of clinical care by ensuring that clinicians have access to the information and guidance they need at both the time and point of care.

PeriGen’s investors include Trident Capital, Galen Partners, and Salmon River Capital.

About PeriGen, Inc.

PeriGen’s advanced clinical decision support and fetal monitoring solutions are installed in leading hospitals and healthcare systems across North America. A pioneer in advanced clinical decision support since 1995, PeriGen provides sophisticated tools and solutions that improve clinical and financial outcomes. PeriGen is a US corporation headquartered in Princeton, New Jersey, with offices in Canada and Israel.